The FY2025 (Dec) proxy of Supernus Pharmaceuticals names 16 peer companies for pay. Among Supernus Pharmaceuticals and these peers, CEO pay was 2nd highest of 5 and total shareholder return was the highest of 5.
2nd highest of 5in Supernus Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:
$7.9M$23.3M
1st highest of 5in Supernus Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:
$17$198
Pay peer group, FY2025 (Dec) proxy
| PTC Therapeutics | ||
| Ultragenyx Pharmaceutical | ||
| Alkermes plc. | ||
| Harmony Biosciences Holdings | ||
| Acadia Pharmaceuticals | Not disclosed | Not disclosed |
| Ani Pharmaceuticals | Not disclosed | Not disclosed |
| Amicus Therapeutics, Inc. | Not disclosed | Not disclosed |
| Amphastar Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Axsome Therapeutics | Not disclosed | Not disclosed |
| Catalyst Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Collegium Pharmaceutical, Inc. | Not disclosed | Not disclosed |
| Corcept Therapeutics | Not disclosed | Not disclosed |
| Dynavax Technologies Corporation | Not disclosed | Not disclosed |
| Ligand Pharmaceuticals | Not disclosed | Not disclosed |
| Pacira Biosciences, Inc. | Not disclosed | Not disclosed |
| Xeris Biopharma Holdings, Inc. | Not disclosed | Not disclosed |
16 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.